We are taking these difficult but necessary actions as we restructure 23andMe, and focus on the long-term success of our core consumer business and research partnerships.
We continue to believe in the promise shown by our clinical and preclinical stage pipeline and will continue to pursue strategic opportunities to continue their development.
Without significant capital, there is substantial doubt it can stay afloat.
We have fulfilled our obligations as a public company amidst significant uncertainty and challenges.
Collection
[
|
...
]